Home/Filings/4/0001652252-19-000051
4//SEC Filing

HERTIA JOHN 4

Accession 0001652252-19-000051

CIK 0000012208other

Filed

Sep 8, 8:00 PM ET

Accepted

Sep 9, 5:50 PM ET

Size

44.9 KB

Accession

0001652252-19-000051

Insider Transaction Report

Form 4
Period: 2019-09-05
HERTIA JOHN
Executive Vice President
Transactions
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-06$326.15/sh+600$195,69022,499 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$336.80/sh1,231$414,60118,697 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$338.97/sh543$184,06117,404 total
  • Tax Payment

    Bio-Rad A Common Stock

    2019-09-05$339.48/sh208$70,61215,299 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$340.00/sh100$34,00017,304 total
  • Tax Payment

    Bio-Rad A Common Stock

    2019-09-07$335.59/sh298$100,00617,606 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-09-062,400600 total
    Exercise: $119.54Exp: 2024-09-10Bio-Rad A Common Stock (2,400 underlying)
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-05+60015,507 total
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-06$119.54/sh+2,400$286,89617,699 total
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-06$139.56/sh+1,800$251,20819,499 total
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-06$159.32/sh+1,200$191,18420,699 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$334.77/sh700$234,33921,799 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$335.64/sh1,871$627,98219,928 total
  • Sale

    Bio-Rad A Common Stock

    2019-09-06$338.01/sh750$253,50817,947 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-09-061,2001,800 total
    Exercise: $215.98Exp: 2027-09-05Bio-Rad A Common Stock (1,200 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2019-09-076001,200 total
    Exercise: $0.00Bio-Rad A Common Stock (600 underlying)
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-06$215.98/sh+1,200$259,17621,899 total
  • Exercise/Conversion

    Bio-Rad A Common Stock

    2019-09-07+60017,904 total
  • Exercise/Conversion

    Restricted Stock Units

    2019-09-056001,800 total
    Exercise: $0.00Bio-Rad A Common Stock (600 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-09-061,8001,200 total
    Exercise: $139.56Exp: 2025-09-11Bio-Rad A Common Stock (1,800 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-09-061,2001,800 total
    Exercise: $159.32Exp: 2026-09-07Bio-Rad A Common Stock (1,200 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-09-066002,400 total
    Exercise: $326.15Exp: 2028-09-04Bio-Rad A Common Stock (600 underlying)
Holdings
  • Bio-Rad A Common Stock

    (indirect: By Spouse)
    252
Footnotes (14)
  • [F1]Shares of Class A common stock acquired on the vesting of restricted stock units.
  • [F10]The option vests in five equal annual installments beginning September 11, 2016.
  • [F11]The option vests in five equal annual installments beginning September 7, 2017.
  • [F12]The option vests in five equal annual installments beginning September 5, 2018.
  • [F13]The option vests in five equal annual installments beginning September 4, 2019.
  • [F14]The restricted stock units vest in five equal annual installments beginning September 7, 2017.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.29 to $335.22, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.32 to $336.24, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.36 to $337.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.63 to $338.44, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $338.63 to $339.17, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F7]Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • [F8]The restricted stock units vest in five equal annual installments beginning September 5, 2018.
  • [F9]The option vests in five equal annual installments beginning September 10, 2015.

Issuer

BIO-RAD LABORATORIES, INC.

CIK 0000012208

Entity typeother

Related Parties

1
  • filerCIK 0001616003

Filing Metadata

Form type
4
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 5:50 PM ET
Size
44.9 KB